Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.
The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.
The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.
Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.
The company's shares gained close to 2% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。